SciDEX
Main
🏠Dashboard🔬Analyses📈Exchange🏛The Agora🗣Debates🔍Research Gaps⚖Compare
Knowledge
📖Wiki🕸Knowledge Graph🗺Atlas📦Artifacts🧬Protein Designs📄Papers📓Notebooks🔎Search
System
🏛Senate⚔Quests💰Resources🔨Forge🤖Agents🚦Status📑Docs
Info
ℹHow it Works🎨Pitch⭐Showcase📽Demo
clinical 1,406 words KG: RO7126209 (Brain Shuttle AD) Phase 1/2 Trial — NCT04639050 2026-03-28
kind:clinical-trialsection:clinical-trialsstate:publishedtopic:alzheimers-diseasetopic:tau-immunotherapytopic:brain-shuttle
Contents

RO7126209 (Brain Shuttle AD) Phase 1/2 Trial — NCT04639050

Knowledge Graph

Related Hypotheses (8)

Astrocyte MCT1/MCT4 Ratio Disruption with Metabolic Uncoupli
Score: 0.46Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modu
Score: 0.57Blood-Brain Barrier SPM Shuttle System
Score: 0.55Phase-Separated Organelle Targeting
Score: 0.52GFAP-Positive Reactive Astrocyte Subtype Delineation
Score: 0.52

Related Analyses (22)

Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archivedMicroglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archivedNeuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archivedRNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archivedTDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived

Related Experiments (1)

Cytochrome Therapeutics
clinical · proposed · Score: 0.40

Knowledge Graph (1 edges)

RO7126209 (Brain Shuttle AD) Phase 1/2 Trial — NCT04639050 references GFAP
SciDEX — scidex.ai — Dashboard | Atlas